Ftse Mib
33.683,16
1,39%
DAX
18.254,18
1,03%
S&P 500
5.471,20
-0,29%
NASDAQ
17.762,35
-0,56%
Bitcoin
64.803,62
-0,25%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Altamira Therapeutics Ltd (CYTO) Altamira Therapeutics Ltd (CYTO) Notizie

Altamira Therapeutics Ltd

CYTO
1,15
-0,10 (-8,00%)
Ultimo aggiornamento: 18:45:12
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/6/202415:01GLOBEAltamira Therapeutics Highlights Newly Published Review..
28/5/202416:31GLOBEAltamira Therapeutics Provides Business Update
23/5/202414:47GLOBEAltamira Therapeutics Announces Dissemination of Positive..
16/5/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/5/202414:47GLOBEAltamira Therapeutics Announces Filing of Provisional Patent..
24/4/202414:47GLOBEAltamira Therapeutics Announces Publication of Positive..
10/4/202414:00GLOBEAltamira Therapeutics Provides Business Update, Reports Full..
04/4/202414:45GLOBEAltamira Therapeutics to Host Full Year 2023 Financial..
25/3/202413:47GLOBEAltamira Therapeutics Announces Collaboration with..
07/2/202414:47GLOBEAltamira Therapeutics’ Peptide-Based Delivery Platform Shown..
24/1/202414:47GLOBEAltamira Therapeutics Files Second Provisional Patent..
22/1/202423:02EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
22/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
19/1/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/1/202422:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202423:02EDGAR2Form F-3 - Registration statement by foreign private issuers
08/1/202414:47GLOBEAltamira Therapeutics to Present at 3rd Annual mRNA-Based..
29/12/202314:47GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
11/12/202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:00GLOBEAltamira Therapeutics Provides Investor and Business Update
08/12/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202318:54GLOBEAltamira Therapeutics to Host Investor & Business Update..
29/11/202316:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
22/11/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202315:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
10/11/202314:47GLOBEAltamira Therapeutics Announces European Patent Office..
31/10/202321:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202314:47GLOBEAltamira Therapeutics Reports Additional Significant..
12/9/202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:30GLOBEAltamira Therapeutics Provides Business Update and First..
06/9/202314:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
23/8/202314:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
21/8/202313:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
28/7/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/7/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/7/202314:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
17/7/202314:47GLOBEAltamira Therapeutics Announces Publication of Positive..
11/7/202314:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/7/202322:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/7/202314:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
30/6/202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 1,25 Min: 1,15 Max: 1,2799
Chiusura: 1,25

La tua Cronologia

NASDAQ
CYTO
Altamira Therapeutics
TIDE
DOGEBTC
Dogecoin
BOV
SEQL11F
Sequoia Logistica e Tran...
COIN
RGSTBTC
BIT
I08682
Intesa Sanpaolo
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network